CRSP

#1281
CRISPR Therapeutics AG - Common Shares
55.4 3 USD
-1.68%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
55.23
56.39
Range Annuel
35.48
78.48
Changement quotidien
-1.68%
Changement Mensuel
+8.01%
Evolution sur 6 mois
+5.98%
Changement Annuel
+50.22%
Clôture Précédente
56.3 8
Open
56.3 6
Low
55.2 3
High
56.3 9
Volume
453
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 5.35 B
  • Employee 393
  • Founded 2013
  • CEO Samarth Kulkarni
  • Website www.crisprtx.com
  • Headquarter Switzerland
  • FIGI UNKNOWN
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-8.11
ratio cours/chiffre d'affaires
1 343.5

CRISPR Therapeutics AG - Common Shares

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration in December 2023.

Nouvelles